The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
ONECUT2 is a driver of neuroendocrine prostate cancer
Open accessAbstract
Neuroendocrine prostate cancer (NEPC), a lethal form of the disease, is characterized by loss of androgen receptor (AR) signaling during neuroendocrine transdifferentiation, which results in resistance to AR-targeted therapy. Clinically, genomically and epigenetically, NEPC resembles other types of poorly differentiated neuroendocrine tumors (NETs). Through pan-NET analyses, we identified ONECUT2 as a candidate master transcriptional regulator of poorly differentiated NETs. ONECUT2 ectopic expression in prostate adenocarcinoma synergizes with hypoxia to suppress androgen signaling and induce neuroendocrine plasticity. ONEUCT2 drives tumor aggressiveness in NEPC, partially through regulating hypoxia signaling and tumor hypoxia. Specifically, ONECUT2 activates SMAD3, which regulates hypoxia signaling through modulating HIF1α chromatin-binding, leading NEPC to exhibit higher degrees of hypoxia compared to prostate adenocarcinomas. Treatment with hypoxia-activated prodrug TH-302 potently reduces NEPC tumor growth. Collectively, these results highlight the synergy between ONECUT2 and hypoxia in driving NEPC, and emphasize the potential of hypoxia-directed therapy for NEPC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Aggarwal, R., Huang, J., Alumkal, J. J., Zhang, L., Feng, F. Y., Thomas, G. V., Weinstein, A. S., Friedl, V., Zhang, C., Witte, O. N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6880 · Cited by 810
Self-citationAndrogen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling
Bluemn, E. G., Coleman, I. M., Lucas, J. M., Coleman, R. T., Hernandez-Lopez, S., Tharakan, R., Bianchi-Frias, D., Dumpit, R. F., Kaipainen, A., Corella, A. N., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.003 · Cited by 744
Lalonde, E., Ishkanian, A. S., Sykes, J., Fraser, M., Ross-Adams, H., Erho, N., Dunning, M. J., Halim, S., Lamb, A. D., Moon, N. C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71021-6 · Cited by 342
Self-citationModulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer
Guo, H., Ahmed, M., Zhang, F., Yao, C. Q., Li, S., Liang, Y., Hua, J., Soares, F., Sun, Y., Langstein, J., et al. (2016) · Nature Genetics · doi:10.1038/ng.3637 · Cited by 226
Self-citationMyt1l safeguards neuronal identity by actively repressing many non-neuronal fates
Mall, M., Kareta, M. S., Chanda, S., Ahlenius, H., Perotti, N., Zhou, B., Grieder, S. D., Ge, X., Drake, S., Euong Ang, C., et al. (2017) · Nature · doi:10.1038/nature21722 · Cited by 225
Age-Dependent Pancreatic Gene Regulation Reveals Mechanisms Governing Human β Cell Function
Arda, H. E., Li, L., Tsai, J., Torre, E. A., Rosli, Y., Peiris, H., Spitale, R. C., Dai, C., Gu, X., Qu, K., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.04.002 · Cited by 222
Wei, Z., Guo, H., Liu, Z., Zhang, X., Liu, Q., Qian, Y., Gong, Y., & Shao, C. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.11.010 · Cited by 30
Self-citation
Cited by
Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions
Chen, Z., Han, F., Du, Y., Shi, H., & Zhou, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01332-8 · Cited by 1,612
Rebello, R. J., Oing, C., Knudsen, K. E., Loeb, S., Johnson, D. C., Reiter, R. E., Gillessen, S., Van der Kwast, T., & Bristow, R. G. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00243-0 · Cited by 1,090
Self-citationTargeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity
Lee, S., Rauch, J., & Kolch, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031102 · Cited by 799
Hypoxia signaling in human health and diseases: implications and prospects for therapeutics
Luo, Z., Tian, M., Yang, G., Tan, Q., Chen, Y., Li, G., Zhang, Q., Li, Y., Wan, P., & Wu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01080-1 · Cited by 499
The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance
Beltran, H., Hruszkewycz, A., Scher, H. I., Hildesheim, J., Isaacs, J., Yu, E. Y., Kelly, K., Lin, D., Dicker, A., Arnold, J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1423 · Cited by 405
Self-citation
Metadata
- Authors
- Guo, H., Ci, X., Ahmed, M., Hua, J. T., Soares, F., Lin, D., Puca, L., Vosoughi, A., Xue, H., Li, E., Su, P., Chen, S., Nguyen, T., Liang, Y., Zhang, Y., Xu, X., Xu, J., Sheahan, A. V., Ba-Alawi, W., Zhang, S., Mahamud, O., Vellanki, R. N., Gleave, M., Bristow, R. G., Haibe-Kains, B., Poirier, J. T., Rudin, C. M., Tsao, M.-S., Wouters, B. G., Fazli, L., Feng, F. Y., Ellis, L., van der Kwast, T., Berlin, A., Koritzinsky, M., Boutros, P. C., Zoubeidi, A., Beltran, H., Wang, Y., & He, H. H.
- Venue
- Nature Communications
- Published
- 2019-01-17
- Volume
- 10
- Issue
- 1
- Pages
- 278-278
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2908623381
- Cited by
- 243
- References
- 8
- FWCI
- 19.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ONECUT2 is a driver of neuroendocrine prostate cancer. https://app.cochat.ai/papers/10.1038/s41467-018-08133-6
- The paper
- Guo, H., Ci, X., Ahmed, M., Hua, J. T., Soares, F., Lin, D., Puca, L., Vosoughi, A., Xue, H., Li, E., Su, P., Chen, S., Nguyen, T., Liang, Y., Zhang, Y., Xu, X., Xu, J., Sheahan, A. V., Ba-Alawi, W., . . . He, H. H. (2019). ONECUT2 is a driver of neuroendocrine prostate cancer. Nature Communications. https://doi.org/10.1038/s41467-018-08133-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.